Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Incidence and Severity of Residual Neuromuscular Blockade With Application of a Protocol for Paralysis and Neostigmine Reversal of Rocuronium

NCT02660398 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02660398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02660398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Incidence and Severity of Residual Neuromuscular Blockade With Application of a Protocol for Paralysis and Neostigmine Reversal of Rocuronium
Lead sponsor
University of Washington
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2016
Completion date
January 31, 2017
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

residual neuromuscular blockade